These agents may help prevent strokes in patients with T2D and established ASCVD.111–113 The SGLT2 inhibitors empagliflozin and canagliflozin have less robust data for MACE prevention but may still be considered to reduce risk of MI and CAD.116–120 Both GLP1-RAs and SGLT2 inhibitors may also be considered in patients with T2D and PAD to reduce the risks of cardiovascular events. This evidence concerns the gene GLP1R and coronary artery disorder.